SEC-sourced researchBeta
BNGO
Bionano Genomics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001411690
- Exchange
- Nasdaq
- Business activity
- — · SIC 3826
- Financial inputs
- 6/6
- Filing date
- Sep 14, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2024 | 30,776,000.0000 | Mar 23, 2026 |
| December 2025 | 28,508,000.0000 | Mar 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 28,508,000.0000 | -26,395,000.0000 | -16,345,000.0000 | 73,584,000.0000 | 29,160,000.0000 | Mar 23, 2026 |
| December 2024 | 30,776,000.0000 | -112,017,000.0000 | -68,922,000.0000 | 76,670,000.0000 | 41,295,000.0000 | Mar 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $28.51M | December 2025 | Mar 23, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $30.78M | December 2024 | Mar 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$26.4M | December 2025 | Mar 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$16.35M | December 2025 | Mar 23, 2026 | 10-K |
| Total assetsAssets | $73.58M | December 2025 | Mar 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $29.16M | December 2025 | Mar 23, 2026 | 10-K |